Did You Know...
...that in the early 1940s GE engineer James Wright was charged with a task of utmost importance to the war effort: develop a cheap substitute for rubber that could be used to produce tires, gas masks and a whole host of military gear. Wright tackled the task diligently -- and wound up inventing Silly Putty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7294483 | Process for producing recombinant polypeptides via a glycerol phosphate or sugar phosphate feed A process is described for producing a polypeptide heterologous to E. coli wherein E. coli cells comprising nucleic acid encoding the polypeptide are cultured in a culture medium while feeding to the culture medium a transportable organophosphate, such... | 11/13/2007 |
| 7229787 | Method of N-terminal cleavage using an aminopeptidase A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negat... | 06/12/2007 |
| 7169908 | Purification of polypeptides A method for purifying a desired heterologous polypeptide from microbial fermentation broth or homogenate in which it is produced and solubilized is described. This method involves adding to the broth or homogenate an effective amount of a solution of 6,9-diamino-2-... | 01/30/2007 |
| RE39355 | Preparation of human IGF via recombinant DNA technology Human insulin-like growth factor is synthesized in recombinant cell culture by host cells transformed with expression vectors bearing DNA encoding human insulin-like growth factor. ... | 10/17/2006 |
| 7084118 | Combination treatment with t-PA variant and low molecular weight heparin The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a ti... | 08/01/2006 |
| 7071300 | IGF antagonist peptides Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers. | 07/04/2006 |
| 7029876 | Process for production of polypeptides Vectors for producing polypeptides heterologous to prokaryotes are described comprising, along with the polypeptide-encoding nucleic acid, anti-termination nucleic acid that inhibits intragenic transcription termination with a non-lambda promoter therefor and/or nuc... | 04/18/2006 |
| 6949349 | Insulin-like growth factor agonist molecules Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal. ... | 09/27/2005 |
| 6921659 | Protease-deficient cells A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negat... | 07/26/2005 |
| 6828121 | Bacterial host strains An E. coli strain is described that is deficient in chromosomal degP and prc encoding protease DegP and Prc, respectively, and harbors a mutant spr gene that encodes a protein that suppresses growth phenotypes exhibited by strains harboring prc mutants. Prefe... | 12/07/2004 |
| 6828118 | Reverse-phase HPLC assay for plasminogen activators A process is described for monitoring the effectiveness of a purification process in removing plasminogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof. This process comprises incubating the sam... | 12/07/2004 |
| 6750321 | Insulin-like growth factor agonist molecules Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal. ... | 06/15/2004 |
| 6743894 | Insulin-like growth factor agonist molecules Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal. ... | 06/01/2004 |
| 6716586 | Insulin-like growth factor agonist molecules Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal. ... | 04/06/2004 |
| 6716602 | Metabolic rate shifts in fermentations expressing recombinant proteins The invention provides a method for increasing product yield of a polypeptide of interest produced by recombinant host cells, where expression of the polypeptide by the recombinant host cells is regulated by an inducible system. More specifically, the method involve... | 04/06/2004 |
| 6713451 | Insulin-like growth factor agonist molecules Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal. ... | 03/30/2004 |
| 6620918 | Separation of polypeptide monomers A method is disclosed for separating a polypeptide monomer from a mixture comprising dimers and/or multimers. The method comprises applying the mixture to either a cation-exchange chromatography resin or an anion-exchange chromatography resin and eluting ... | 09/16/2003 |
| 6610516 | Cell culture process A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding a glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt and ... | 08/26/2003 |
| 6593097 | Reverse-phase HPLC assay for plasminogen activators A process is described for monitoring the effectiveness of a purification process in removing plasminogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof. This process comprises incubat... | 07/15/2003 |
| 6559122 | Formulated composition A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobu... | 05/06/2003 |
| 6509443 | IGF-I point variants IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.... | 01/21/2003 |
| 6506874 | IGF-I variants IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.... | 01/14/2003 |
| 6506598 | Cell culture process A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding said glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt a... | 01/14/2003 |
| 6455262 | Receptor polypeptides and their production and uses An isolated TGF-ଲ supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also pr... | 09/24/2002 |
| 6420518 | Insulin-like growth factor agonist molecules Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.... | 07/16/2002 |
| 6403764 | Insulin-like growth factor-1 protein variants IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16,25,49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, ... | 06/11/2002 |
| 6331609 | Preparation of human IGF via recombinant DNA technology Human insulin-like growth factor is synthesized in recombinant cell culture by host cells transformed with expression vectors bearing DNA encoding human insulin-like growth factor.... | 12/18/2001 |
| 6331414 | Preparation of human IGF via recombinant DNA technology Human insulin-like growth factors is synthesized in recombinant cell culture by host cells transformed with expression vectors bearing DNA encoding human insulin-like growth factors.... | 12/18/2001 |
| 6313285 | Purification of plasmid DNA A process is described for purifying plasmid DNA from prokaryotic cells comprised thereof. This process comprises the steps of: (a) digesting the cells; (b) incubating the cells for about 4 to 24 hours to effect lysis and solubilization thereof, without e... | 11/06/2001 |
| 6258560 | Process for bacterial production of polypeptides Processes are described for recovering heterologous polypeptide from bacterial cells, including the periplasm and cytoplasm. One process involves culturing the bacterial cells, which cells comprise nucleic acid encoding phage lysozyme and nucleic acid enc... | 07/10/2001 |
| 6251865 | Insulin-like growth factor agonist molecules Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mam... | 06/26/2001 |
| 6180367 | Process for bacterial production of polypeptides Processes are described for recovering heterologous polypeptide from bacterial cells, including the periplasm and cytoplasm. One process involves culturing the bacterial cells, which cells comprise nucleic acid encoding phage lysozyme and nucleic acid enc... | 01/30/2001 |
| 6140128 | Preparation of calcium phosphate transfectacons A process is described for preparing transfectacons, or particles, of calcium phosphate and a desired nucleic acid comprising admixing calcium divalent cation, phosphate multivalent anion, and the desired nucleic acid to form a precipitation mixture, wher... | 10/31/2000 |
| 6121416 | Insulin-like growth factor agonist molecules Compounds are provided that prevent the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mam... | 09/19/2000 |
| 6114137 | Assay using marked microbial host cell strains An assay is provided for determining the presence of contaminating microbial host cells in a culturing vessel containing a microbial host cell strain that utilizes more than one carbohydrate source as a substrate comprising: (a) culturing the microbial ho... | 09/05/2000 |
| 5962252 | Assay using marked microbial host cell strains An assay is provided for determining the presence of contaminating microbial host cells in a culturing vessel containing a microbial host cell strain that utilizes more than one carbohydrate source as a substrate comprising: (a) culturing the microbial ho... | 10/05/1999 |
| 5935924 | Treatment of congestive heart failure A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and in... | 08/10/1999 |
| 5808006 | Refolding of polypeptides like recombinant insulin-like growth factor IGF-I A composition is provided comprising about 0.1 to 15 mg/ml of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, ... | 09/15/1998 |
| 5789199 | Process for bacterial production of polypeptides A process is provided for producing a heterologous polypeptide in bacteria. This process comprises, in a first step, culturing bacterial cells that lack their native pstS gene and comprise nucleic acid encoding a PstS variant having an amino acid variatio... | 08/04/1998 |
| 5783556 | Formulated insulin-containing composition Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and... | 07/21/1998 |
